- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05594576
Comparison of the ENDOCUFF VISION® Endoscopy Cap Coupled With GI GENIUS™ Artificial Intelligence Compared to Each Device Alone in Improving Colonic Adenoma Detection Rate During Colonoscopy (COLODETECT2)
Colorectal cancer is the 2nd most common cause of death by cancer. Screening is therefore essential, with a positive impact for prevention, and in the visualization and removal of colonic adenomas, pre-cancerous lesions of colorectal cancer.
The colonic adenoma detection rate (CADR), the gold standard for colonoscopy screening and screening studies, is the ratio of the number of colonoscopies with at least one histologically verified colonic adenoma to the total number of colonoscopies performed in a center. It varies between 25 and 45% depending on the center. There is a large inter-operator CADR variability, which has been linked to an increased incidence and excess mortality in colorectal cancers.
To improve this detection rate, several innovative techniques have been developed:
The endoscopic cap helps improve this detection rate: it is a 2cm tip with double row of plastic wings, fixed to the distal end of the colonoscope, which acts by unfolding the colonic haustrations allowing a better visualization of adenomas, and more particularly those of sessile morphology and sigmoidal location. Several multicenter studies have shown an improvement in the adenoma detection rate with this device compared to screening colonoscopy alone, with an adenoma detection rate optimization of 14%. Since then other devices, such as the Endocuff, have emerged with comparable efficacy. The Medtronic© GI GENIUS system integrates artificial intelligence (AI) to assist in the detection of polyps. It automatically identifies these precancerous lesions in real time.
The study investigators previously performed a retrospective pilot study (COLODETECT), comparing colonoscopy alone as a control group, against AI alone and against the combined cap + AI. This study showed encouraging results in terms of colonic adenoma detection rate (60% for the AI + cap group versus 37% for the AI alone group versus 33% for the colonoscopy alone group, p=0.037) However, it requires a higher level of evidence to be validated in practice. This prospective COLODETECT2 study estimated an a priori expected difference between A.I. - Cap and A.I. alone of about 15% CADR.
The GI GENIUS artificial intelligence system and the ENDOCUFF VISION endoscopic cap have separately proven their effectiveness in terms of colonic adenoma detection compared to colonoscopy alone. However, some limitations remain: existence of false positives (mucosal folds, residues), some morphological types still difficult to recognize (scalloped adenomas), non visualized colonic lesions.
This study therefore focuses on the possible complementarity of these 2 medical devices, in order to maximize the detection rate of colonic adenomas, and thus overcome the limitations of these two techniques by optimizing the visualization of these precancerous lesions, and consequently increasing the impact of colorectal cancer screening.
The study authors hypothesize that the combination of GI GENIUS™ AI coupled with the ENDOCUFF VISION® endoscopy cap provides a better colonic adenoma detection rate (CAD) during colonoscopy than either GI GENIUS™ AI alone or the ENDOCUFF VISION® cap alone.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ludovic Caillo
- Phone Number: 04.66.68.37.94
- Email: ludovic.caillo@chu-nimes.fr
Study Locations
-
-
-
Limoges, France, 87000
- Recruiting
- CHU de Limoges
-
Contact:
- Jérémie JACQUES
- Phone Number: 0555058772
- Email: Jeremie.jacques@chu-limoges.fr
-
Nîmes, France
- Recruiting
- Chu de Nimes
-
Contact:
- Anissa Megzari
- Phone Number: 04.66.68.42.36
- Email: drc@chu-nimes.fr
-
Principal Investigator:
- Ludovic CAILLO
-
Sub-Investigator:
- Jean-François BOURGAUX
-
Sub-Investigator:
- Philippe POUDEROUX
-
Sub-Investigator:
- Clémentine CLERC
-
Sub-Investigator:
- Bénédicte BRUNAUD-GAGNIARD
-
Sub-Investigator:
- Thomas BORDERIE
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Need to perform colorectal cancer screening colonoscopy:
- Primary Screening: Fecal Immunological Test positive;
- Secondary screening: personal or family history of polyps, personal or family history of colorectal cancer, rectorrhagia-like symptomatology.
- Patient candidate for outpatient management.
- Patient who has given free and informed consent.
- Patient who has signed the consent form.
- Patient affiliated or beneficiary of a health insurance plan.
Exclusion Criteria:
- The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
- The subject refuses to sign the consent
- It is impossible to give the subject informed information
- The patient is under safeguard of justice or state guardianship
- History of inflammatory bowel disease, Crohn's disease.
- Failure of a previous colonoscopy.
- Known familial polyposis.
- Contraindication to polypectomy (coagulation disorder, treatment with CLOPIDOGREL / anticoagulant).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ENDOCUFF VISION® Endoscopic Cap coupled with GI GENIUS™ Artificial Intelligence (AI)
|
Device used during coloscopy for detection of colonic adenoma
Device used during coloscopy for detection of colonic adenoma
|
Active Comparator: GI GENIUS™ Artificial Intelligence (AI) alone
|
Device used during coloscopy for detection of colonic adenoma
|
Active Comparator: ENDOCUFF VISION® endoscopic cap alone
|
Device used during coloscopy for detection of colonic adenoma
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare colonic adenoma detection rates (CADR) during colonoscopy between the three groups
Time Frame: Day 0
|
%; defined as the number of colonoscopies with detection of at least one colonic adenoma out of the total number of colonoscopies performed
|
Day 0
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operator effect on CADR, between the three groups, per operator
Time Frame: Day 0
|
CADR (%), defined as the number of colonoscopies with detection of at least one colonic adenoma out of the total number of colonoscopies performed for each strategy per operator
|
Day 0
|
CADR according to adenoma size, for each strategy
Time Frame: Day 0
|
CADR (%), detected by colonoscopy according to their size in mm (especially those smaller than 3 mm)
|
Day 0
|
CADR according to adenoma histology for each strategy.
Time Frame: Day 0
|
CADR (%), detected by colonoscopy according to histology (low/high grade dysplasia)
|
Day 0
|
CADR according to adenoma morphology for each strategy.
Time Frame: Day 0
|
CADR (%), detected by colonoscopy according to (Paris morphological classification: Ip, Is, IIa, IIb, IIc, III)
|
Day 0
|
Shrinkage time for the Genius groups.
Time Frame: Day 0
|
Measurement of withdrawal time (min, sec) for GI GENIUS™-Cap software or GI GENIUS™ software alone strategies (time from cecum to colonoscope removal).
|
Day 0
|
Rate of cecal intubation between groups
Time Frame: Day 0
|
% of exams in which the entire colon was examined.
|
Day 0
|
Progression time between groups
Time Frame: Day 0
|
Mean progression time (time from introduction of colonoscope to cecum; min, sec
|
Day 0
|
Operative time between groups
Time Frame: Day 0
|
Mean time from introduction of colonoscope to removal of endoscope from patient; min, sec
|
Day 0
|
The number of immediate intra- and postoperative adverse events (bleeding, perforation) according to the different strategies
Time Frame: Day 0
|
Collection of immediate intra- and postoperative adverse events (bleeding, perforation) for the three study strategies
|
Day 0
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ludovic Caillo, Chu de Nimes
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NIMAO/2021-2/LC-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Cancer
-
University of California, San FranciscoCompletedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRectal Cancer | Colon Cancer | Cancer Survivor | Colorectal Adenocarcinoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer Survivor | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal Cancer AJCC v8 | Stage IIB Colorectal... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingColorectal Adenocarcinoma | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage... and other conditionsUnited States
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
University of Roma La SapienzaCompletedColorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Cancer Stage 0 | Colorectal Cancer Stage IItaly
-
Sidney Kimmel Cancer Center at Thomas Jefferson...United States Department of DefenseActive, not recruitingColorectal Adenoma | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 | Stage 0 Colorectal Cancer AJCC v8 | Stage I Colorectal Cancer AJCC v8 | Stage II Colorectal Cancer AJCC v8 | Stage IIA Colorectal... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); AmgenTerminatedStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...United States
Clinical Trials on GI GENIUS™ artificial intelligence system
-
Smart Medical Systems Ltd.Not yet recruitingAdenoma | Colorectal (Colon or Rectal) CancerUnited States
-
Hospital Universitario La FeMedtronic; European Society of Gastrointestinal EndoscopyRecruiting
-
Cosmo Artificial Intelligence-AI LtdCompletedArtificial IntelligenceItaly
-
Elucid Labs Inc.UnknownMelanoma (Skin) | Squamous Cell Carcinoma of the Skin | Basal Cell Carcinoma of the SkinCanada
-
Centre hospitalier de l'Université de Montréal...University of British Columbia; McGill University; Université de Sherbrooke; University...RecruitingArtificial IntelligenceCanada
-
The Third Xiangya Hospital of Central South UniversityRecruitingClinical Research on a Novel Deep-learning Based System in Pancreatic Endoscopic Ultrasound ScanningPancreatic DiseaseChina
-
Renmin Hospital of Wuhan UniversityCompletedTraining | Artificial Intelligence | GastroscopyChina
-
Renmin Hospital of Wuhan UniversityNot yet recruitingArtificial Intelligence | ColonoscopyChina
-
Renmin Hospital of Wuhan UniversityRecruitingArtificial Intelligence | EndoscopyChina
-
Renmin Hospital of Wuhan UniversityNot yet recruiting